Defining Favorable Prognosis in Bone Metastatic Hormone‐Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors
This risk model suggests that patients without ≥ 11 BM, ≥ GS9, and ≥ cT3b may benefit from ARSI plus androgen deprivation therapy for mHSPC. Moreover, it identifies a significantly larger favorable-risk subgroup than the CHAARTED criteria, potentially enhancing clinical precision in treatment selection.
Authors
- Tetsuo Satoh
- Shuhei Hirano (ORCID: https://orcid.org/0009-0007-6851-8665)
- Shinji Kurosaka
- Kohei Mori
- Kazumasa Matsumoto (ORCID: https://orcid.org/0009-0007-9465-5161)
- Ken-ichi Tabata
- Dai Koguchi
- Hideyasu Tsumura
- Junichiro Ishii
- Daisuke Ishii
- Masaomi Ikeda
Institutions
- National Sagamihara Hospital (JP)
- International University Of Health And Welfare Atami Hospital (JP)
- Kitasato Institute Hospital (JP)
- Kitasato University (JP)
Publication Details
- Journal
- The Prostate
- Published
- 2026-03-03
- DOI
- https://doi.org/10.1002/pros.70152
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00